Mersana Therapeutics (MRSN) has disclosed a new risk, in the Capital Markets category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mersana Therapeutics faces significant business risks due to the uncertainty surrounding U.S. trade policy, particularly the tariffs imposed by the Trump Administration. The 10% baseline reciprocal tariff on all U.S. trading partners, along with higher tariffs on China, Canada, and Mexico, could adversely affect the company’s supply chain and increase production costs. Additionally, the ongoing Section 232 investigation into pharmaceutical imports may lead to further tariffs, exacerbating potential disruptions. These factors could delay the development and approval of Mersana’s product candidates, posing a material threat to its financial condition and operational results.
Overall, Wall Street has a Strong Buy consensus rating on MRSN stock based on 6 Buys and 1 Hold.
To learn more about Mersana Therapeutics’ risk factors, click here.